meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions

Peritoneal Dialysis ComplicationEnd Stage Kidney DiseaseSodium-glucose Co-transporter-2 InhibitorsKidney DysfunctionResidual Kidney Function

Interventions

DRUG

Empagliflozin 25 MG

PO once daily

Trial Locations (1)

RECRUITING

Toronto General Hospital, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER